Oncopeptides

Aging Population And Precision Oncology Will Open New Markets

AnalystHighTarget

Not Invested

Community Contributor

Published

17 Aug 25

AnalystHighTarget's Fair Value

SEK 4.50

28.0% overvalued

17 Aug

SEK 5.76

167.9%

8.9%

167.9%

8.9%

You can edit this narrative until Aug 17 10:01 PM. Then, changes will post as Updates.

Author's Valuation

SEK 4.528.0% overvalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

SEK 4.5

28.0% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

66.20%

Biotech revenue growth rate

8.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.92%

Calculation

SEK 41.13m

Earnings '28

32.85x

PE Ratio '28

SEK 1.35b

Market Cap '28

SEK 1.35b

Market Cap '28

260.70m

No. shares '28

SEK 5.18

Share Price '28

SEK 5.18 Share Price '28

Discounted to 2025 @ 4.92% p.a.

SEK 4.49

Fair Value '25